NCT06312826
Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 11 words Show 6 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Nov 2025 to Sep 15, 2025
- Enrollment target: estimated 806 to confirmed 805
- Study completion date changed from estimate of Dec 2027 to Mar 30, 2026
- Secondary endpoints: 6 to 5
- Publications: details revised at 1 of 1 entry
- Notable Lead sponsor: So Yeon Kim to Asan Medical Center
- Secondary endpoints: 3 to 6
- Collaborators expanded, about 1 word
- Notable Primary completion date: Dec 2024 to Nov 2025
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 2 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Detection rate of patients with early stage HCC
Timeframe: 6 months after the completion of the 2 surveillance rounds
Secondary (5)
False referral rate
Detection rate of patients with very early stage HCC
Detection rate of patients with all-stage HCC
Stage distribution at initial HCC diagnosis
Receipt of curative-intent treatment
Arms and interventions
US groupActive comparator
Subjects will be evaluated by two rounds of tests with abdominal US for the surveillance of HCC at intervals of 6 months.
AMRI groupExperimental
Subjects will be evaluated by two rounds of tests with AMRI for the surveillance of HCC at intervals of 6 months.
Procedures: Abdominal US, AMRI
Sites
1 site in 1 country
- Asan Medical CenterSeoul, Songpa-gu, South Korea